Timothy Garrington
Concepts (322)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Central Nervous System Neoplasms | 2 | 2024 | 158 | 0.710 |
Why?
| | Rhabdomyosarcoma | 1 | 2019 | 72 | 0.580 |
Why?
| | Sarcoma, Ewing | 3 | 2025 | 95 | 0.570 |
Why?
| | MAP Kinase Kinase Kinases | 6 | 2004 | 73 | 0.530 |
Why?
| | Kidney Neoplasms | 4 | 2025 | 400 | 0.500 |
Why?
| | Mitogen-Activated Protein Kinases | 8 | 2004 | 313 | 0.410 |
Why?
| | Hodgkin Disease | 2 | 2016 | 139 | 0.390 |
Why?
| | Wilms Tumor | 2 | 2025 | 86 | 0.350 |
Why?
| | Neuroblastoma | 3 | 2017 | 160 | 0.330 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 4 | 2004 | 134 | 0.310 |
Why?
| | Neoplasms | 6 | 2025 | 2644 | 0.310 |
Why?
| | Beckwith-Wiedemann Syndrome | 1 | 2008 | 6 | 0.310 |
Why?
| | Adrenal Gland Neoplasms | 2 | 2014 | 89 | 0.300 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2009 | 135 | 0.300 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2008 | 57 | 0.290 |
Why?
| | Asparaginase | 2 | 1998 | 30 | 0.290 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 5 | 2004 | 162 | 0.290 |
Why?
| | Positron-Emission Tomography | 1 | 2009 | 295 | 0.280 |
Why?
| | MAP Kinase Kinase Kinase 1 | 3 | 2005 | 19 | 0.280 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2008 | 63 | 0.280 |
Why?
| | Histiocytosis, Langerhans-Cell | 2 | 2020 | 38 | 0.270 |
Why?
| | Pancreatitis | 2 | 1998 | 132 | 0.270 |
Why?
| | Child | 24 | 2025 | 21968 | 0.260 |
Why?
| | Child, Preschool | 18 | 2025 | 11069 | 0.250 |
Why?
| | MAP Kinase Kinase Kinase 2 | 7 | 2012 | 12 | 0.250 |
Why?
| | Teratoma | 2 | 2025 | 114 | 0.250 |
Why?
| | Mast Cells | 3 | 2003 | 146 | 0.240 |
Why?
| | Nose Neoplasms | 1 | 2025 | 25 | 0.240 |
Why?
| | Carcinosarcoma | 1 | 2025 | 21 | 0.230 |
Why?
| | Testicular Neoplasms | 2 | 2017 | 110 | 0.230 |
Why?
| | Adaptor Proteins, Signal Transducing | 4 | 2003 | 429 | 0.230 |
Why?
| | Genetic Heterogeneity | 1 | 2025 | 59 | 0.230 |
Why?
| | Clonal Evolution | 1 | 2025 | 45 | 0.230 |
Why?
| | Appointments and Schedules | 1 | 2025 | 89 | 0.230 |
Why?
| | Adolescent | 20 | 2025 | 21463 | 0.220 |
Why?
| | Paclitaxel | 1 | 2025 | 227 | 0.220 |
Why?
| | Medical Errors | 1 | 2025 | 110 | 0.210 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2004 | 87 | 0.210 |
Why?
| | Catheterization, Central Venous | 1 | 2025 | 111 | 0.210 |
Why?
| | Biomarkers, Tumor | 3 | 2025 | 1274 | 0.210 |
Why?
| | Central Nervous System Diseases | 1 | 2024 | 69 | 0.200 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2016 | 77 | 0.200 |
Why?
| | MAP Kinase Signaling System | 3 | 2008 | 321 | 0.200 |
Why?
| | Lung Neoplasms | 2 | 2021 | 2491 | 0.200 |
Why?
| | Neoplasms, Second Primary | 1 | 2024 | 115 | 0.200 |
Why?
| | Bone Neoplasms | 1 | 2025 | 248 | 0.200 |
Why?
| | Parental Leave | 1 | 2022 | 26 | 0.190 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 310 | 0.190 |
Why?
| | Anemia | 1 | 2023 | 170 | 0.190 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 182 | 0.190 |
Why?
| | Thrombocytopenia | 1 | 2023 | 199 | 0.180 |
Why?
| | Sarcoma | 2 | 2015 | 191 | 0.180 |
Why?
| | Pulmonary Blastoma | 1 | 2021 | 8 | 0.180 |
Why?
| | Tomography, X-Ray Computed | 2 | 2021 | 2677 | 0.180 |
Why?
| | RNA, Neoplasm | 1 | 2021 | 82 | 0.180 |
Why?
| | Circulating Tumor DNA | 1 | 2021 | 34 | 0.170 |
Why?
| | Stem Cell Factor | 1 | 2000 | 15 | 0.170 |
Why?
| | Pituitary Diseases | 1 | 2020 | 21 | 0.170 |
Why?
| | Ribonuclease III | 1 | 2021 | 40 | 0.170 |
Why?
| | Cholestasis | 1 | 2023 | 232 | 0.170 |
Why?
| | Sertoli-Leydig Cell Tumor | 1 | 2020 | 8 | 0.170 |
Why?
| | Receptors, IgE | 1 | 2000 | 45 | 0.170 |
Why?
| | Rhabdomyosarcoma, Embryonal | 1 | 2020 | 22 | 0.170 |
Why?
| | Fibroblasts | 3 | 2005 | 989 | 0.170 |
Why?
| | Infant | 12 | 2025 | 9442 | 0.170 |
Why?
| | DEAD-box RNA Helicases | 1 | 2021 | 76 | 0.170 |
Why?
| | Pituitary Gland | 1 | 2020 | 149 | 0.170 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2020 | 31 | 0.160 |
Why?
| | Humans | 39 | 2025 | 136783 | 0.160 |
Why?
| | Survival Rate | 3 | 2019 | 1969 | 0.160 |
Why?
| | Salvage Therapy | 2 | 2025 | 142 | 0.150 |
Why?
| | Fellowships and Scholarships | 1 | 2022 | 306 | 0.150 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2025 | 1055 | 0.150 |
Why?
| | Disease-Free Survival | 2 | 2019 | 687 | 0.150 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 226 | 0.150 |
Why?
| | Polycystic Kidney Diseases | 1 | 2019 | 76 | 0.150 |
Why?
| | Female | 23 | 2025 | 72840 | 0.150 |
Why?
| | Male | 23 | 2025 | 67361 | 0.140 |
Why?
| | Octreotide | 1 | 1998 | 26 | 0.140 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2017 | 14 | 0.140 |
Why?
| | Antibodies, Neutralizing | 1 | 2020 | 282 | 0.140 |
Why?
| | Abdominal Neoplasms | 1 | 2017 | 39 | 0.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2025 | 1683 | 0.140 |
Why?
| | Cancer Survivors | 1 | 2022 | 279 | 0.130 |
Why?
| | Cytodiagnosis | 1 | 2017 | 33 | 0.130 |
Why?
| | Frozen Sections | 1 | 2017 | 26 | 0.130 |
Why?
| | Seminoma | 1 | 2017 | 20 | 0.130 |
Why?
| | Interferon-gamma | 1 | 2020 | 790 | 0.130 |
Why?
| | Quality Improvement | 1 | 2025 | 1152 | 0.130 |
Why?
| | Cytokines | 2 | 2004 | 2088 | 0.130 |
Why?
| | Protein Processing, Post-Translational | 1 | 1999 | 467 | 0.130 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2003 | 1242 | 0.130 |
Why?
| | Enzyme Activation | 6 | 2004 | 813 | 0.130 |
Why?
| | Retrospective Studies | 8 | 2025 | 15564 | 0.120 |
Why?
| | Health Planning | 1 | 2015 | 47 | 0.120 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 1999 | 404 | 0.120 |
Why?
| | Ovarian Neoplasms | 1 | 2020 | 563 | 0.110 |
Why?
| | Thoracoscopy | 1 | 2014 | 56 | 0.110 |
Why?
| | Mediastinal Neoplasms | 1 | 2014 | 45 | 0.110 |
Why?
| | Transcription Factor AP-1 | 2 | 2005 | 92 | 0.110 |
Why?
| | Transition to Adult Care | 1 | 2015 | 81 | 0.110 |
Why?
| | Genetic Predisposition to Disease | 2 | 2021 | 2417 | 0.110 |
Why?
| | Arabinonucleosides | 1 | 2013 | 8 | 0.110 |
Why?
| | Adenine Nucleotides | 1 | 2013 | 23 | 0.110 |
Why?
| | Xanthogranuloma, Juvenile | 1 | 2013 | 6 | 0.110 |
Why?
| | Histiocytosis, Sinus | 1 | 2013 | 8 | 0.110 |
Why?
| | Disease Management | 2 | 2015 | 623 | 0.110 |
Why?
| | Biopsy | 1 | 2017 | 1126 | 0.110 |
Why?
| | Carrier Proteins | 4 | 2003 | 768 | 0.110 |
Why?
| | Ambulatory Care Facilities | 1 | 2015 | 230 | 0.100 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2013 | 94 | 0.100 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1428 | 0.100 |
Why?
| | Heart Diseases | 1 | 2016 | 359 | 0.100 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2012 | 145 | 0.090 |
Why?
| | Prognosis | 5 | 2025 | 4018 | 0.090 |
Why?
| | Prevalence | 1 | 2019 | 2712 | 0.090 |
Why?
| | Diagnostic Imaging | 1 | 2014 | 331 | 0.090 |
Why?
| | Anesthesia | 1 | 2014 | 191 | 0.090 |
Why?
| | Gene Expression Regulation | 4 | 2012 | 2603 | 0.090 |
Why?
| | Receptors, Tumor Necrosis Factor | 2 | 2002 | 164 | 0.090 |
Why?
| | Signal Transduction | 3 | 2004 | 5065 | 0.090 |
Why?
| | Program Development | 2 | 2015 | 365 | 0.080 |
Why?
| | Ventricular Remodeling | 1 | 2012 | 262 | 0.080 |
Why?
| | Stem Cells | 2 | 2008 | 590 | 0.080 |
Why?
| | Laparoscopy | 1 | 2014 | 464 | 0.080 |
Why?
| | Pediatrics | 2 | 2008 | 1112 | 0.080 |
Why?
| | Subtraction Technique | 1 | 2009 | 23 | 0.080 |
Why?
| | Primary Health Care | 2 | 2022 | 1714 | 0.080 |
Why?
| | Young Adult | 7 | 2025 | 13126 | 0.080 |
Why?
| | Radiopharmaceuticals | 1 | 2009 | 178 | 0.080 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2008 | 50 | 0.070 |
Why?
| | Myocytes, Cardiac | 1 | 2012 | 528 | 0.070 |
Why?
| | Adult | 7 | 2025 | 37616 | 0.070 |
Why?
| | Mutation | 4 | 2025 | 3953 | 0.070 |
Why?
| | Polymerase Chain Reaction | 2 | 2021 | 1059 | 0.070 |
Why?
| | Heart Ventricles | 1 | 2012 | 792 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 1998 | 2129 | 0.070 |
Why?
| | Infant, Newborn | 4 | 2023 | 6046 | 0.070 |
Why?
| | Embryo, Mammalian | 2 | 2005 | 231 | 0.070 |
Why?
| | Mitogen-Activated Protein Kinase 7 | 4 | 2012 | 21 | 0.060 |
Why?
| | Leukemia | 1 | 2008 | 238 | 0.060 |
Why?
| | Liver Neoplasms | 1 | 2012 | 784 | 0.060 |
Why?
| | Risk Assessment | 1 | 2015 | 3429 | 0.060 |
Why?
| | Near Miss, Healthcare | 1 | 2025 | 11 | 0.060 |
Why?
| | Hypoxia | 1 | 2012 | 1107 | 0.060 |
Why?
| | Epidermal Growth Factor | 2 | 2003 | 174 | 0.060 |
Why?
| | Age Factors | 3 | 2018 | 3290 | 0.060 |
Why?
| | Cell Line | 5 | 2003 | 2836 | 0.060 |
Why?
| | Acute Disease | 2 | 1998 | 1006 | 0.060 |
Why?
| | Education, Medical, Undergraduate | 1 | 2007 | 186 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2005 | 55 | 0.060 |
Why?
| | Transcription Factors | 2 | 2021 | 1714 | 0.060 |
Why?
| | Killer Cells, Natural | 1 | 2008 | 445 | 0.060 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2005 | 99 | 0.060 |
Why?
| | SEER Program | 2 | 2016 | 218 | 0.060 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2025 | 80 | 0.060 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2004 | 29 | 0.060 |
Why?
| | Phosphorylation | 3 | 2012 | 1756 | 0.060 |
Why?
| | DNA Copy Number Variations | 1 | 2025 | 182 | 0.050 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2025 | 190 | 0.050 |
Why?
| | Genes, jun | 1 | 2003 | 10 | 0.050 |
Why?
| | Blotting, Western | 2 | 2004 | 1225 | 0.050 |
Why?
| | Apoptosis | 3 | 2002 | 2548 | 0.050 |
Why?
| | Myogenic Regulatory Factors | 1 | 2003 | 57 | 0.050 |
Why?
| | Survival Analysis | 2 | 2018 | 1319 | 0.050 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 654 | 0.050 |
Why?
| | DNA Methylation | 1 | 2008 | 644 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 1 | 2004 | 386 | 0.050 |
Why?
| | beta Catenin | 1 | 2025 | 251 | 0.050 |
Why?
| | Macromolecular Substances | 2 | 2003 | 229 | 0.050 |
Why?
| | Promoter Regions, Genetic | 3 | 2005 | 1250 | 0.050 |
Why?
| | Tissue Donors | 1 | 2005 | 417 | 0.050 |
Why?
| | src-Family Kinases | 1 | 2003 | 92 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 451 | 0.050 |
Why?
| | Animals | 9 | 2012 | 36768 | 0.050 |
Why?
| | Mice | 6 | 2012 | 17731 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2012 | 2999 | 0.050 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 288 | 0.050 |
Why?
| | Recurrence | 3 | 2013 | 1058 | 0.050 |
Why?
| | Academic Medical Centers | 1 | 2025 | 497 | 0.050 |
Why?
| | Cell Differentiation | 2 | 2000 | 1980 | 0.050 |
Why?
| | Survivors | 2 | 2016 | 487 | 0.050 |
Why?
| | Central Nervous System | 1 | 2024 | 258 | 0.050 |
Why?
| | Databases, Factual | 2 | 2018 | 1347 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 849 | 0.050 |
Why?
| | Cells, Cultured | 3 | 2005 | 4194 | 0.050 |
Why?
| | Survivorship | 1 | 2022 | 49 | 0.050 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2008 | 434 | 0.040 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2021 | 24 | 0.040 |
Why?
| | RNA-Binding Protein EWS | 1 | 2021 | 25 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2012 | 1902 | 0.040 |
Why?
| | Kidney Diseases, Cystic | 1 | 2021 | 24 | 0.040 |
Why?
| | Receptor Aggregation | 1 | 2000 | 11 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2025 | 671 | 0.040 |
Why?
| | Transcription, Genetic | 2 | 2005 | 1453 | 0.040 |
Why?
| | Curriculum | 1 | 2007 | 979 | 0.040 |
Why?
| | Pneumothorax | 1 | 2021 | 38 | 0.040 |
Why?
| | Translocation, Genetic | 1 | 2021 | 104 | 0.040 |
Why?
| | Reoviridae | 1 | 2000 | 37 | 0.040 |
Why?
| | Chemokine CXCL9 | 1 | 2020 | 27 | 0.040 |
Why?
| | Syndrome | 1 | 2021 | 357 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2021 | 172 | 0.040 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2000 | 376 | 0.040 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2000 | 282 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 5749 | 0.040 |
Why?
| | Mating Factor | 1 | 1999 | 3 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 1999 | 52 | 0.040 |
Why?
| | Receptors, Growth Factor | 1 | 1999 | 55 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2020 | 5115 | 0.040 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2021 | 214 | 0.040 |
Why?
| | Growth Substances | 1 | 1999 | 147 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2025 | 1396 | 0.040 |
Why?
| | Insect Proteins | 1 | 1999 | 39 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2002 | 646 | 0.040 |
Why?
| | TRPP Cation Channels | 1 | 2019 | 84 | 0.040 |
Why?
| | Fungal Proteins | 1 | 1999 | 134 | 0.040 |
Why?
| | Transcriptional Activation | 1 | 2000 | 378 | 0.040 |
Why?
| | Age of Onset | 1 | 2020 | 518 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2022 | 481 | 0.040 |
Why?
| | MAP Kinase Kinase 5 | 3 | 2003 | 4 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2025 | 1768 | 0.040 |
Why?
| | Cytoskeleton | 1 | 1999 | 186 | 0.040 |
Why?
| | Chronic Disease | 2 | 2015 | 1784 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 891 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2000 | 500 | 0.030 |
Why?
| | Dexamethasone | 1 | 2020 | 377 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1500 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1235 | 0.030 |
Why?
| | Mammals | 1 | 1999 | 283 | 0.030 |
Why?
| | Receptors, Cell Surface | 1 | 2019 | 386 | 0.030 |
Why?
| | United States | 3 | 2022 | 14660 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 1059 | 0.030 |
Why?
| | Drosophila melanogaster | 1 | 1999 | 228 | 0.030 |
Why?
| | Hepatoblastoma | 1 | 2017 | 46 | 0.030 |
Why?
| | Intraoperative Period | 1 | 2017 | 59 | 0.030 |
Why?
| | Incidence | 1 | 2024 | 2788 | 0.030 |
Why?
| | Microtubules | 1 | 1999 | 270 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 495 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2016 | 60 | 0.030 |
Why?
| | Stress, Physiological | 1 | 1999 | 442 | 0.030 |
Why?
| | Caenorhabditis elegans | 1 | 1999 | 305 | 0.030 |
Why?
| | Time Factors | 2 | 2018 | 6792 | 0.030 |
Why?
| | Neurilemmoma | 1 | 2014 | 24 | 0.030 |
Why?
| | Organizational Innovation | 1 | 2015 | 138 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 615 | 0.030 |
Why?
| | Saccharomyces cerevisiae | 1 | 1999 | 558 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2015 | 192 | 0.030 |
Why?
| | Parents | 1 | 2022 | 1355 | 0.030 |
Why?
| | Peptides | 1 | 1999 | 980 | 0.030 |
Why?
| | Lymphoma | 1 | 2014 | 206 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3272 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2017 | 1373 | 0.020 |
Why?
| | MAP Kinase Kinase 7 | 2 | 2003 | 8 | 0.020 |
Why?
| | Logistic Models | 1 | 2018 | 2060 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2000 | 2831 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2015 | 1318 | 0.020 |
Why?
| | Two-Hybrid System Techniques | 2 | 2003 | 59 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2000 | 1998 | 0.020 |
Why?
| | Colorado | 2 | 2015 | 4491 | 0.020 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 2 | 2002 | 30 | 0.020 |
Why?
| | fas Receptor | 2 | 2002 | 95 | 0.020 |
Why?
| | Program Evaluation | 1 | 2015 | 886 | 0.020 |
Why?
| | Caspases | 2 | 2002 | 247 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2020 | 10764 | 0.020 |
Why?
| | Aged | 2 | 2022 | 23729 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2012 | 514 | 0.020 |
Why?
| | Transfection | 2 | 2003 | 945 | 0.020 |
Why?
| | Receptor, IGF Type 1 | 1 | 2008 | 65 | 0.020 |
Why?
| | Ultrasonography | 1 | 2012 | 751 | 0.020 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2008 | 105 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1294 | 0.020 |
Why?
| | Drug Design | 1 | 2008 | 166 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2008 | 286 | 0.020 |
Why?
| | Schools, Medical | 1 | 2007 | 146 | 0.020 |
Why?
| | Pancreatic Neoplasms | 1 | 2014 | 931 | 0.020 |
Why?
| | Clinical Clerkship | 1 | 2007 | 98 | 0.020 |
Why?
| | Medical Oncology | 1 | 2008 | 290 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 544 | 0.020 |
Why?
| | Histocompatibility Testing | 1 | 2005 | 126 | 0.020 |
Why?
| | Protein Binding | 2 | 2003 | 2223 | 0.010 |
Why?
| | Fos-Related Antigen-2 | 1 | 2005 | 1 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 2005 | 51 | 0.010 |
Why?
| | Prospective Studies | 1 | 2017 | 7583 | 0.010 |
Why?
| | Urokinase-Type Plasminogen Activator | 1 | 2005 | 29 | 0.010 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2005 | 150 | 0.010 |
Why?
| | Middle Aged | 2 | 2017 | 33200 | 0.010 |
Why?
| | Dimerization | 1 | 2005 | 198 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 2005 | 415 | 0.010 |
Why?
| | Faculty, Medical | 1 | 2007 | 282 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2016 | 7569 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2008 | 1181 | 0.010 |
Why?
| | MEF2 Transcription Factors | 1 | 2003 | 61 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2008 | 1043 | 0.010 |
Why?
| | Graft vs Host Disease | 1 | 2005 | 249 | 0.010 |
Why?
| | Mink | 1 | 2003 | 12 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2003 | 170 | 0.010 |
Why?
| | Amino Acid Motifs | 1 | 2003 | 225 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2012 | 4279 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2005 | 1513 | 0.010 |
Why?
| | Cell Nucleus | 1 | 2005 | 614 | 0.010 |
Why?
| | Caspase 3 | 1 | 2002 | 246 | 0.010 |
Why?
| | Models, Biological | 1 | 2008 | 1769 | 0.010 |
Why?
| | Base Sequence | 1 | 2005 | 2180 | 0.010 |
Why?
| | MAP Kinase Kinase Kinase 3 | 1 | 2000 | 4 | 0.010 |
Why?
| | Fas-Associated Death Domain Protein | 1 | 2000 | 9 | 0.010 |
Why?
| | Caspase 8 | 1 | 2000 | 48 | 0.010 |
Why?
| | Caspase 9 | 1 | 2000 | 57 | 0.010 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2000 | 51 | 0.010 |
Why?
| | COS Cells | 1 | 2000 | 188 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2002 | 365 | 0.010 |
Why?
| | Antigen-Presenting Cells | 1 | 2000 | 156 | 0.010 |
Why?
| | Caspase Inhibitors | 1 | 2000 | 81 | 0.010 |
Why?
| | Oxidants | 1 | 2000 | 110 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2903 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2002 | 436 | 0.010 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2000 | 188 | 0.010 |
Why?
| | Hydrogen Peroxide | 1 | 2000 | 320 | 0.010 |
Why?
| | Mitosis | 1 | 1999 | 193 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2003 | 1093 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 2000 | 1150 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2003 | 1309 | 0.010 |
Why?
| | Kidney | 1 | 2003 | 1463 | 0.010 |
Why?
|
|
Garrington's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|